AI-generated from publicly available materials.Evaxion has decided to discontinue its solid tumor vaccine, EVX-03, in order to focus on a brain cancer candidate developed in collaboration with Duke University.
The Danish biotech previously aimed to advance EVX-03, a DNA vaccine intended for non-small cell lung cancer (NSCLC), but plans for clinical trials never materialized. Despite initial optimism regarding its potential across multiple indications, the vaccine has been sidelined as Evaxion reallocates its resources to other projects.
In its recent quarterly earnings report, Evaxion announced the termination of EVX-03 as part of a strategic portfolio management decision. Insights gained from this program are being applied to its two leading candidates, EVX-05 and EVX-04. EVX-05 is positioned as an innovative off-the-shelf therapeutic vaccine targeting glioblastoma, designed using patient tumor samples and leveraging the company's AI-Immunology platform to focus on specific endogenous retrovirus-derived antigens.
This collaboration with Duke University aims to optimize the vaccine for a phase 1 trial, which is critical given the limited treatment options available for glioblastoma patients. The use of ERV-antigens as targets may represent a significant advancement in cancer treatment, potentially improving patient outcomes. Evaxion is also pursuing a similar approach with EVX-04, aimed at acute myeloid leukemia, which is currently in preclinical stages. With the discontinuation of EVX-03, the company’s financial strategy appears to secure its operations through 2027, allowing it to concentrate on these promising candidates.